Hand eczema affects about 10% of the general population and can have a significant impact on quality of life, especially in social interactions, occupational successes, and daily life activities.
No consistent correlation between etiology and clinical pattern exist. While some patients with mild cases respond well to either lifestyle changes or medical interventions, no consistent and effective treatment regime exists for severe cases.
In multiple double-blind, randomized clinical trials, the efficacy of Dupilumab has demonstrated positive results in three patients with palm eczema, and therefore, may be considered an option for treatment.
Read more about this study at the Journal of the American Academy of Dermatology. (Open Access.)
Work Cited:
Dupilumab for hand eczema, Zirwas, Matthew J., Journal of the American Academy of Dermatology, Volume 79, Issue 1, 167 – 169